论文征集:PLOS医学特刊:细菌抗菌素耐药性监测和预防

IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL PLoS Medicine Pub Date : 2022-05-01 DOI:10.1371/journal.pmed.1004014
{"title":"论文征集:PLOS医学特刊:细菌抗菌素耐药性监测和预防","authors":"","doi":"10.1371/journal.pmed.1004014","DOIUrl":null,"url":null,"abstract":"The editors of PLOS Medicine, together with guest editors Timothy Walsh, Ramanan Laxminarayan and Ana Cristina Gales, announce a forthcoming Special Issue dedicated to bacterial antimicrobial resistance (AMR). Research submissions are now being invited. The emergence of pathogenic bacteria which cannot be effectively treated with existing drugs has been prioritised by the World Health Organization as one of the top ten global public health threats facing humanity [1]. Drug-resistant infections are associated with substantial morbidity and mortality, and were estimated to contribute to 4.95 million deaths globally in 2019 [2]. The burden of antimicrobial resistance (AMR) is disproportionately observed in lowand middleincome countries (LMICs), particularly sub-Saharan Africa [2]. Without intervention, it has been estimated that global deaths attributable to AMR could reach 10 million annually by 2050 [3]. AMR is a One Health problem and its causes lie in human, animal and environmental domains. The overuse and misuse of antibiotics, and the potential for transmission within and between these domains is responsible for the rapid global spread of drug-resistant pathogens. Use of antibiotics increased by 65% globally between 2000 and 2015, and more than doubled in LMICs over the same period [4]. Pathogen AMR evolution can limit the effectiveness of available antibiotics and far outpaces our ability to develop new drugs. Of the 32 antibiotics in clinical development to tackle priority pathogens in 2019, only six were classified as innovative [5]. Action to impede the development of drug-resistance is urgently required. The guest editors and PLOS Medicine editors seek high-quality and high-impact research submissions related to the main drivers, surveillance and prevention of bacterial antimicrobial resistance, particularly in lowand middle-income settings. Areas of particular interest include the prevalence and clinical challenges of drug-resistant bacteria, interventions to reduce disease transmission, diagnostics informing antimicrobial prescribing, misuse and overuse of antimicrobials, economics of antimicrobial access and use, and One Health interventions to reduce AMR. Submission of articles related to pathogens of highest concern and highest global burden (excluding Mycobacterium tuberculosis) are strongly encouraged. Please see plos.io/AMR for more detailed information. To submit your manuscript for consideration, please visit http://journals.plos.org/ plosmedicine/s/submit-now, indicating your interest in the Special Issue in your cover letter. Questions about the Special Issue can be directed to plosmedicine@plos.org. The submission deadline is July 15 2022.","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":" ","pages":""},"PeriodicalIF":10.5000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Call for Papers: PLOS Medicine Special Issue on Bacterial Antimicrobial Resistance—Surveillance and Prevention\",\"authors\":\"\",\"doi\":\"10.1371/journal.pmed.1004014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The editors of PLOS Medicine, together with guest editors Timothy Walsh, Ramanan Laxminarayan and Ana Cristina Gales, announce a forthcoming Special Issue dedicated to bacterial antimicrobial resistance (AMR). Research submissions are now being invited. The emergence of pathogenic bacteria which cannot be effectively treated with existing drugs has been prioritised by the World Health Organization as one of the top ten global public health threats facing humanity [1]. Drug-resistant infections are associated with substantial morbidity and mortality, and were estimated to contribute to 4.95 million deaths globally in 2019 [2]. The burden of antimicrobial resistance (AMR) is disproportionately observed in lowand middleincome countries (LMICs), particularly sub-Saharan Africa [2]. Without intervention, it has been estimated that global deaths attributable to AMR could reach 10 million annually by 2050 [3]. AMR is a One Health problem and its causes lie in human, animal and environmental domains. The overuse and misuse of antibiotics, and the potential for transmission within and between these domains is responsible for the rapid global spread of drug-resistant pathogens. Use of antibiotics increased by 65% globally between 2000 and 2015, and more than doubled in LMICs over the same period [4]. Pathogen AMR evolution can limit the effectiveness of available antibiotics and far outpaces our ability to develop new drugs. Of the 32 antibiotics in clinical development to tackle priority pathogens in 2019, only six were classified as innovative [5]. Action to impede the development of drug-resistance is urgently required. The guest editors and PLOS Medicine editors seek high-quality and high-impact research submissions related to the main drivers, surveillance and prevention of bacterial antimicrobial resistance, particularly in lowand middle-income settings. Areas of particular interest include the prevalence and clinical challenges of drug-resistant bacteria, interventions to reduce disease transmission, diagnostics informing antimicrobial prescribing, misuse and overuse of antimicrobials, economics of antimicrobial access and use, and One Health interventions to reduce AMR. Submission of articles related to pathogens of highest concern and highest global burden (excluding Mycobacterium tuberculosis) are strongly encouraged. Please see plos.io/AMR for more detailed information. To submit your manuscript for consideration, please visit http://journals.plos.org/ plosmedicine/s/submit-now, indicating your interest in the Special Issue in your cover letter. Questions about the Special Issue can be directed to plosmedicine@plos.org. The submission deadline is July 15 2022.\",\"PeriodicalId\":20368,\"journal\":{\"name\":\"PLoS Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":10.5000,\"publicationDate\":\"2022-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PLoS Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1371/journal.pmed.1004014\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PLoS Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1371/journal.pmed.1004014","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 1

摘要

《公共科学图书馆·医学》的编辑与客座编辑Timothy Walsh、Ramanan Laxminarayan和Ana Cristina Gales一起宣布即将出版的细菌抗微生物耐药性特刊。现在正在邀请提交研究报告。世界卫生组织将无法用现有药物有效治疗的致病菌的出现列为人类面临的十大全球公共卫生威胁之一[1]。耐药性感染与严重的发病率和死亡率有关,据估计,2019年全球有495万人死亡[2]。在中低收入国家,特别是撒哈拉以南非洲,抗菌药物耐药性(AMR)的负担不成比例[2]。据估计,如果不进行干预,到2050年,全球每年因AMR导致的死亡人数可能达到1000万[3]。AMR是一个单一健康问题,其原因在于人类、动物和环境领域。抗生素的过度使用和滥用,以及在这些领域内和之间传播的可能性,是耐药病原体在全球迅速传播的原因。2000年至2015年间,全球抗生素的使用量增加了65%,同期LMIC的使用量翻了一番多[4]。病原体AMR的进化会限制现有抗生素的有效性,远远超过我们开发新药的能力。在2019年临床开发的32种抗生素中,只有6种被归类为创新[5]。迫切需要采取行动阻止耐药性的发展。客座编辑和PLOS Medicine编辑寻求与细菌抗微生物耐药性的主要驱动因素、监测和预防相关的高质量、高影响力的研究报告,特别是在中低收入环境中。特别感兴趣的领域包括耐药细菌的流行率和临床挑战、减少疾病传播的干预措施、为抗菌药物处方提供信息的诊断、抗菌药物的滥用和过度使用、抗菌药物获取和使用的经济性,以及减少AMR的One Health干预措施。强烈鼓励提交与最受关注和全球负担最高的病原体(不包括结核分枝杆菌)有关的文章。有关更多详细信息,请参阅plos.io/AMR。要提交您的手稿供考虑,请访问http://journals.plos.org/plosmedicine/s/立即提交,在求职信中表明您对特刊的兴趣。有关特刊的问题,请访问plosmedicine@plos.org.提交截止日期为2022年7月15日。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Call for Papers: PLOS Medicine Special Issue on Bacterial Antimicrobial Resistance—Surveillance and Prevention
The editors of PLOS Medicine, together with guest editors Timothy Walsh, Ramanan Laxminarayan and Ana Cristina Gales, announce a forthcoming Special Issue dedicated to bacterial antimicrobial resistance (AMR). Research submissions are now being invited. The emergence of pathogenic bacteria which cannot be effectively treated with existing drugs has been prioritised by the World Health Organization as one of the top ten global public health threats facing humanity [1]. Drug-resistant infections are associated with substantial morbidity and mortality, and were estimated to contribute to 4.95 million deaths globally in 2019 [2]. The burden of antimicrobial resistance (AMR) is disproportionately observed in lowand middleincome countries (LMICs), particularly sub-Saharan Africa [2]. Without intervention, it has been estimated that global deaths attributable to AMR could reach 10 million annually by 2050 [3]. AMR is a One Health problem and its causes lie in human, animal and environmental domains. The overuse and misuse of antibiotics, and the potential for transmission within and between these domains is responsible for the rapid global spread of drug-resistant pathogens. Use of antibiotics increased by 65% globally between 2000 and 2015, and more than doubled in LMICs over the same period [4]. Pathogen AMR evolution can limit the effectiveness of available antibiotics and far outpaces our ability to develop new drugs. Of the 32 antibiotics in clinical development to tackle priority pathogens in 2019, only six were classified as innovative [5]. Action to impede the development of drug-resistance is urgently required. The guest editors and PLOS Medicine editors seek high-quality and high-impact research submissions related to the main drivers, surveillance and prevention of bacterial antimicrobial resistance, particularly in lowand middle-income settings. Areas of particular interest include the prevalence and clinical challenges of drug-resistant bacteria, interventions to reduce disease transmission, diagnostics informing antimicrobial prescribing, misuse and overuse of antimicrobials, economics of antimicrobial access and use, and One Health interventions to reduce AMR. Submission of articles related to pathogens of highest concern and highest global burden (excluding Mycobacterium tuberculosis) are strongly encouraged. Please see plos.io/AMR for more detailed information. To submit your manuscript for consideration, please visit http://journals.plos.org/ plosmedicine/s/submit-now, indicating your interest in the Special Issue in your cover letter. Questions about the Special Issue can be directed to plosmedicine@plos.org. The submission deadline is July 15 2022.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
PLoS Medicine
PLoS Medicine 医学-医学:内科
CiteScore
21.60
自引率
0.60%
发文量
227
审稿时长
3 months
期刊介绍: PLOS Medicine aims to be a leading platform for research and analysis on the global health challenges faced by humanity. The journal covers a wide range of topics, including biomedicine, the environment, society, and politics, that affect the well-being of individuals worldwide. It particularly highlights studies that contribute to clinical practice, health policy, or our understanding of disease mechanisms, with the ultimate goal of improving health outcomes in diverse settings. Unwavering in its commitment to ethical standards, PLOS Medicine ensures integrity in medical publishing. This includes actively managing and transparently disclosing any conflicts of interest during the reporting, peer review, and publication processes. The journal promotes transparency by providing visibility into the review and publication procedures. It also encourages data sharing and the reuse of published work. Author rights are upheld, allowing them to retain copyright. Furthermore, PLOS Medicine strongly supports Open Access publishing, making research articles freely available to all without restrictions, facilitating widespread dissemination of knowledge. The journal does not endorse drug or medical device advertising and refrains from exclusive sales of reprints to avoid conflicts of interest.
期刊最新文献
Impact on beer sales of removing the pint serving size: An A-B-A reversal trial in pubs, bars, and restaurants in England Behavioral risk factors and socioeconomic inequalities in ischemic heart disease mortality in the United States: A causal mediation analysis using record linkage data Is C-reactive protein sufficient to guide antimicrobial therapy for lower respiratory tract infections among children? Results from a stepped-wedge cluster randomized trial in Uganda. The cost-effectiveness of preventing, diagnosing, and treating postpartum haemorrhage: A systematic review of economic evaluations Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1